MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)

The Oncotype DX DCIS assay is covered only for women with ductal carcinoma in situ who plan to undergo breast-conserving surgery and are contemplating adjuvant radiation therapy. The policy provides limited coverage restricted to this clinical scenario; no additional documentation, frequency limits, or other indications are specified in the provided excerpt.

"Oncotype DX DCIS assay is covered for women diagnosed with ductal carcinoma in situ (DCIS) who are planning breast-conserving surgery and are considering adjuvant radiation therapy."

Sign up to see full coverage criteria, indications, and limitations.